Artivion (NYSE:AORT) Given Buy Rating at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Artivion (NYSE:AORT) in a research note issued to investors on Tuesday,Benzinga reports. Needham & Company LLC currently has a $34.00 price target on the stock.

Other equities analysts have also issued reports about the company. Oppenheimer upped their target price on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. JMP Securities restated a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Artivion has a consensus rating of “Buy” and a consensus target price of $31.80.

Artivion Trading Up 1.3 %

NYSE AORT opened at $31.04 on Tuesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. Artivion has a one year low of $16.48 and a one year high of $32.33. The company has a 50-day simple moving average of $29.32 and a 200-day simple moving average of $27.39. The firm has a market capitalization of $1.30 billion, a PE ratio of -1,551.75 and a beta of 1.74.

Insider Buying and Selling

In other Artivion news, CAO Amy Horton sold 4,329 shares of the firm’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $29.66, for a total transaction of $128,398.14. Following the transaction, the chief accounting officer now owns 135,660 shares of the company’s stock, valued at approximately $4,023,675.60. This trade represents a 3.09 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jean F. Holloway sold 8,070 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total transaction of $243,068.40. Following the sale, the senior vice president now owns 153,862 shares in the company, valued at $4,634,323.44. This trade represents a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 20,017 shares of company stock valued at $600,007 in the last three months. 8.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Artivion

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AORT. FMR LLC raised its stake in shares of Artivion by 28.0% in the 3rd quarter. FMR LLC now owns 115,184 shares of the company’s stock worth $3,066,000 after buying an additional 25,176 shares in the last quarter. Barclays PLC raised its position in Artivion by 346.3% in the third quarter. Barclays PLC now owns 70,877 shares of the company’s stock worth $1,888,000 after acquiring an additional 54,996 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in Artivion in the 3rd quarter valued at about $5,798,000. JPMorgan Chase & Co. grew its stake in shares of Artivion by 394.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock worth $2,606,000 after purchasing an additional 78,120 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Artivion by 58.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after purchasing an additional 125,668 shares during the last quarter. 86.37% of the stock is owned by institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.